DasiSimulations
DASI Simulations develops FDA-cleared AI-powered digital twin software that generates patient-specific simulations of TAVR and other structural heart procedures to support pre-operative planning, sold via enterprise licensing to hospitals, health systems, and interventional cardiology and cardiac surgery teams.
- Company typePrivate
- Founded2019
- HeadquartersDublin, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What DasiSimulations does
DASI Simulations is a privately held medical technology company that develops AI-powered digital twin simulation software for pre-operative planning of structural heart interventions, principally transcatheter aortic valve replacement (TAVR). The company's core technology ingests patient CT imaging data, applies computer vision and computational predictive modeling to construct patient-specific 3D digital twins of cardiac anatomy, and simulates how specific valve frames expand within that anatomy to forecast procedural complications such as leaflet thrombosis, hypoattenuating leaflet thickening (HALT), and coronary obstruction.
Its product portfolio centers on the FDA 510(k)-cleared PrecisionTAVI planning tool (cleared 2022) and a second FDA-cleared AI-powered imaging product (cleared 2024), with an upcoming DASI Simulations Treatment App (expected 2026) designed to extend planning capabilities to broader structural heart disease workflows via mobile and web. The company monetizes through a B2B enterprise software licensing/subscription model, selling directly to hospitals and integrated health systems via a consultative "Request a Demo" field-sales motion; pricing is quote-based and not publicly disclosed. Reference customers include Cleveland Clinic, Sentara, Piedmont Healthcare, Wexner Medical Center (Ohio State University), and Baylor Scott & White, and the company has established strategic co-development partnerships with Cleveland Clinic and Medtronic to validate and distribute its TAVR planning technology. The company is a Georgia Tech spinout (previously branded DasiSim), headquartered in Dublin, Ohio, with 11–50 employees and over $7 million in total disclosed funding as of early 2024.
DasiSimulations firmographics
Firmographics- Name
- DasiSimulations
- Legal name
- DASI Simulations LLC
- Website
- https://dasisim.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- DASI Simulations develops FDA-cleared AI-powered digital twin software that generates patient-specific simulations of TAVR and other structural heart procedures to support pre-operative planning, sold via enterprise licensing to hospitals, health systems, and interventional cardiology and cardiac surgery teams.
- Ownership category
- akta.pro rank
DasiSimulations industry classification
Industry- Product category
- Cardiac Surgical Planning Software
- NAICS
- Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451), Surgical and Medical Instrument Manufacturing (339112), Computer Systems Design and Related Services (54151)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Condition-specific Digital Therapeutics (DTx) (HLACANAA)
- akta.pro secondary industry
- Healthcare & Clinical Simulation (Surgery, Nursing, EMT, Patient Interaction) (EDAFAJAC)
Keywords
Where DasiSimulations is headquartered
LocationHeadquarters
- HQ city
- Dublin
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
DasiSimulations business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations
Revenue model
- Software Licensing/Subscription: B2B licensing model providing hospitals and health systems access to DASI's AI-powered predictive modeling software for cardiac procedure planning. The software is deployed to health systems in multiple states, suggesting a subscription or per-procedure licensing structure typical of medical device software.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels6 records
DasiSimulations product offering
Product offeringCore offering
DASI Simulations develops and licenses an AI-powered digital twin simulation platform that generates patient-specific 3D models of the heart from CT imaging data to plan structural heart procedures such as TAVR. Its FDA 510(k)-cleared product, PrecisionTAVI, predicts procedural complications including leaflet thrombosis and coronary obstruction, enabling interventional cardiologists and cardiac surgeons to virtually test valve platforms and implant strategies before surgery.
Product overview
DASI Simulations offers a platform-based portfolio centered on its Digital Twin Simulation Platform, which powers the FDA-cleared PrecisionTAVI product for TAVR planning. An upcoming DASI Simulations Treatment App extends the platform's capabilities to broader structural heart disease planning. The company also maintains an active pipeline of AI-driven products at various stages of development, including a second FDA-cleared AI imaging product. All offerings are designed for use by interventional cardiologists and cardiac surgeons in hospital settings.
Differentiator
Problem solved
Functional benefit
Products and services
- PrecisionTAVI FDA 510(k)-cleared AI-powered prediction tool for transcatheter aortic valve replacement (TAVR) planning. Uses patient-specific digital twin simulations to forecast procedural complications including valve thrombosis, hypoattenuating leaflet thickening (HALT), and coronary obstruction, enabling personalized surgical planning for interventional cardiologists and cardiac surgeons.
- Digital Twin Simulation Platform Core AI-powered computational platform that generates patient-specific 3D digital twin models of the heart from CT imaging data. Dynamically models valve frame expansion and procedural outcomes, supporting planning across TAVR and other structural heart interventions for hospital-based cardiology teams.
- DASI Simulations Treatment App Upcoming mobile and desktop application designed to extend DASI's structural heart disease planning capabilities, offering clinicians enhanced visualization and optimization of treatment options to improve patient outcomes.
Quantifiable outcome
- Reduced unnecessary leaflet modification procedures by over 70%, allowing complex interventions only for patients at highest risk
Companies that use DasiSimulations
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles1 record
DasiSimulations technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature4 records
DasiSimulations partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- MedtroniccoreMedtronic and DASI Simulations announced a strategic partnership to develop AI-driven predictive modeling and digital twin technology for enhancing TAVR planning in the United States. The solution aims to provide clinicians with accurate, personalized insights to improve procedural outcomes and mitigate risks, supporting a shift towards data-driven, patient-specific care in structural heart disease treatment.
- Cleveland CliniccoreCleveland Clinic partnered with DASI Simulations to validate and co-develop AI-powered predictive modeling technology for transcatheter aortic valve replacement (TAVR) procedures. The clinical validation process began in late 2025 and is expected to last six months to a year. The partnership aims to elevate TAVR care standards and potentially expand the technology to other structural heart procedures like mitral and tricuspid valve interventions.
- Georgia TechminorGeorgia Tech commercialization programs have supported DASI Simulations as a spinout, with access to bench-to-patient commercialization programs including funding mechanisms like CREATE-X, Biolocity, and Georgia Research Alliance grants. Georgia Tech's commercialization team helps navigate FDA regulatory pathways and capital raising.
Scale indicators3 records
Recent moves6 records
Expansion highlights6 records
DasiSimulations competitors and assessment
Company assessmentDirect peers
- HeartFlow: HeartFlow applies AI-driven computational modeling to coronary CT to produce patient-specific 3D models (FFR-CT) for non-invasive coronary disease assessment. Like DASI, it sells an FDA-cleared SaaMD that uses patient-specific imaging and predictive modeling to plan cardiac interventions at health systems, often via enterprise subscriptions.
- FEops (now part of Abbott): FEops developed AI-enabled patient-specific simulation for TAVR and other structural heart procedures before being acquired by Abbott. It is the closest direct competitor to DASI's PrecisionTAVI: same indication (TAVR), same digital twin approach to predicting post-implant complications, and now embedded inside a major structural heart device manufacturer.
- Circle Cardiovascular Imaging: Circle CVI provides cardiac MR, CT, and advanced visualization software used in structural heart and TAVR planning at hospitals and core labs. It directly overlaps with DASI in TAVR/CT-based pre-procedural planning workflows and sells enterprise software into the same cardiology customers.
Broad incumbents
- Philips HeartNavigator: Philips HeartNavigator is a 3D planning and guidance suite for structural heart and TAVR procedures integrated with Philips' broader cardiology imaging portfolio. It competes with DASI as an incumbent enterprise platform with deep hospital penetration and serves the same heart-team buyers.
- Siemens Healthineers (syngo.via, HeartSciences): Siemens offers syngo.via and CT/cardiology planning software widely used in TAVR/structural heart workflows. As a major imaging OEM, it competes with DASI by bundling planning capabilities into installed CT scanners and cath-lab systems at large hospital systems.
- Edwards Lifesciences: Edwards is the dominant US TAVR device manufacturer (Sapien platform) and a primary customer/partner ecosystem for any TAVR planning software. It is a key counterparty for DASI's commercial pathway and could either integrate, partner with, or compete against digital twin planning tools.
- Abbott Structural Heart: Abbott's structural heart franchise (including acquired FEops capability) makes it both a potential competitor and a strategic partner for AI-driven TAVR planning. It operates in the same cath-lab and heart-team buying centers as DASI and represents the largest installed-base competitor in digital planning.
Emerging players
- Materialise (HeartPrint / Mimics): Materialise offers patient-specific 3D anatomical modeling and 3D-printed surgical planning across cardiac, orthopedic, and CMF use cases. It overlaps with DASI in patient-specific 3D modeling for complex procedures and competes for the same enterprise hospital planning budgets.
- TomTec / Philips Ultrasound: TomTec (now part of Philips) provides advanced cardiac imaging analysis and 3D echo-based planning tools used in structural heart workflows. It is comparable to DASI as a software-only planning layer for interventional cardiologists, though typically anchored to echo rather than CT digital twins.
- VirtaMed: VirtaMed provides simulation-based training and procedure rehearsal tools for interventional cardiology and structural heart. It overlaps with DASI in the use of simulation/digital twin concepts for cardiac procedure planning, though its core focus is physician training rather than patient-specific pre-op planning.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
DasiSimulations social profiles
Digital presenceDasiSimulations compliance and trust
Trust signalCompliance1 record
DasiSimulations financial estimates
Financial estimateRevenue estimate
Valuation estimate
DasiSimulations leadership team
Management profileNumber of profiles
Profiles2 records
DasiSimulations funding detail
Funding detailFunding overview
Funding rounds7 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
DasiSimulations M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about DasiSimulations
What does DasiSimulations do?
DASI Simulations develops and licenses an AI-powered digital twin simulation platform that generates patient-specific 3D models of the heart from CT imaging data to plan structural heart procedures such as TAVR. Its FDA 510(k)-cleared product, PrecisionTAVI, predicts procedural complications including leaflet thrombosis and coronary obstruction, enabling interventional cardiologists and cardiac surgeons to virtually test valve platforms and implant strategies before surgery.
Is DasiSimulations a public or private company?
DasiSimulations is a private company. It is classified as venture growth investor backed and is currently operating.
When was DasiSimulations founded?
DasiSimulations was founded in 2019. It employs 11 to 50 people.
Where is DasiSimulations based?
DasiSimulations is headquartered in Dublin, United States, in the North America region.
How does DasiSimulations make money?
One revenue line is on record: software Licensing/Subscription.
Who are DasiSimulations's main competitors?
Direct peers on record are HeartFlow, FEops (now part of Abbott) and Circle Cardiovascular Imaging. Broad incumbents are Philips HeartNavigator, Siemens Healthineers (syngo.via, HeartSciences), Edwards Lifesciences and Abbott Structural Heart. Emerging players are Materialise (HeartPrint / Mimics), TomTec / Philips Ultrasound and VirtaMed.
Does DasiSimulations have an API?
No public API is recorded for DasiSimulations.
What industry is DasiSimulations in?
DasiSimulations's product category is Cardiac Surgical Planning Software. Its primary akta.pro industry code is HLACANAA, Condition-specific Digital Therapeutics (DTx), with a secondary code of EDAFAJAC, Healthcare & Clinical Simulation (Surgery, Nursing, EMT, Patient Interaction). Its NAICS code is 33451 and its SIC code is 3841.